Manipulation of avidity to improve effectiveness of adoptively transferred CD8+ T cells for melanoma immunotherapy in human MHC class I-transgenic mice

Journal of Immunology

Volumn 167, Issue 10, 2001, Pages 5824-5831

  Bullock, T N J ^a   Mullins, D W ^a   Colella, T A ^a   Engelhard, V H ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; GAMMA INTERFERON; GLYCOPROTEIN GP 100; HLA ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MONOPHENOL MONOOXYGENASE; PEPTIDE;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL MODEL; ANTIGEN RECOGNITION; ARTICLE; CANCER IMMUNOTHERAPY; CROSS REACTION; DENDRITIC CELL; IMMUNIZATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN VARIANT; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TRANSGENIC MOUSE; TUMOR GROWTH;

EID: 0035889923     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.167.10.5824     Document Type: Article

References (47)

1. Direct identification of tumor-associated peptide antigens
2. Human tumor antigens for cancer vaccine development
3. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines
4. Recognition of shared melanoma antigens in association with major HLA-A alleles by tumor infiltrating T lymphocytes from 123 patients with melanoma
5. Self-tolerance to the murine homologue of a tyrosinase-derived melanoma antigen: Implications for tumor immunotherapy
6. The density of peptides displayed by dendritic cells affects immune responses to human tyrosinase and gp100 in HLA-A2 transgenic mice
7. Recombinant virus vaccination against "self" antigens using anchor-fixed immunogens
8. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma: A preliminary report
9. Prospects for adoptive T cell therapy
10. Identification of human cancers deficient in antigen processing
11. Tumor escape from immune response by variation in HLA expression and other mechanisms
12. Detection of antigen-specific T cells with multivalent soluble class II MHC covalent peptide complexes
13. A kinetic basis for T cell receptor repertoire selection during an immune response
14. + T lymphocytes that persist after peripheral tolerance to a self antigen expressed in the pancreas
15. T cell affinity maturation by selective expansion during infection
16. Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers
17. Cutting edge: Rapid cloning of tumor-specific CTL suitable for adoptive immunotherapy of melanoma
18. Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy
19. High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy
20. Importance of MHC class I α2 and α3 domains in the recognition of self and non-self MHC molecules
21. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor
22. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues
23. Specificity of the immune response to the 2,4-dinitrophenyl and 2,4,6-trinitrophenyl groups: Ligand binding and fluorescence properties of cross-reacting antibodies
24. Heteroclitic antibodies: Differences in fine specificities between monoclonal antibodies directed against dinitrophenyl and trinitrophenyl haptens
25. gp100/pmel 17 is a murine tumor rejection antigen: Induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand
26. Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma
27. Induction of anti-tumor immunity using dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens
28. The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes
29. Assessment of immunogenicity of human Melan-A peptide analogues in HLA-A*020I/Kb transgenic mice
30. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
31. Separation of IL-4 production from Th cell proliferation by an altered T cell receptor ligand
32. Relationships among TCR ligand potency, thresholds for effector function elicitation, and the quality of early signaling events in human T cells
33. Kinetics of T-cell receptor binding to peptide/I-Ek complexes: Correlation of the dissociation rate with T-cell responsiveness
34. Qualitative and quantitative differences in T cell receptor binding of agonist and antagonist ligands
35. Conversion of a T cell antagonist into an agonist by repairing a defect in the TCR/peptide/MHC interface: Implications for TCR signaling
36. Peptide antagonism and T cell receptor interactions with peptide-MHC complexes
37. Lack of strict correlation of functional sensitization with the apparent affinity of MHC/peptide complexes for the TCR
38. Critical role for CD8 in T cell receptor binding and activation by peptide/major histocompatibility complex multimers
39. + T cells in the thymus
40. + T cells without selection of higher affinity TCR
41. + T cells
42. Increased TCR avidity after T cell activation: A mechanism for sensing low-density antigen
43. T lymphocyte costimulation mediated by reorganization of membrane microdomains
44. The amplification of TCR signaling by dynamic membrane microdomains
45. Two intermediate-avidity cytotoxic T lymphocyte clones with a disparity between functional avidity and MHC tetramer staining
46. Efficient T cell activation requires an optimal dwell-time of interaction between the TCR and the pMHC complex
47. Immune responses to the HLA-A*0201-restricted epitopes of tyrosinase and gp100 enable control of melanoma outgrowth in HLA-A*0201-transgenic mice